SCIENTIFIC REPORTS

natureresearch

Check for updates

OPEN Comparison of intradialytic versus home-based exercise programs on physical functioning, physical activity level, adherence, and health-related quality of life: pilot study

Lucía Ortega-Pérez de Villar^{1,2,4 \Box}, Francisco José Martínez-Olmos ^{1,4}, Francisco de Borja Pérez-Domínguez¹, Vicent Benavent-Caballer^{1,4}, Francisco Javier Montañez-Aguilera^{1,4}, Tom Mercer^{3,5} & Eva Segura-Ortí^{1,4}}

Intradialytic exercise (ID) programs are effective and safe for hemodialysis (HD) patients to avoid functional deterioration. However, exercise is not routinely undertaken in most HD units, and we do not know if home-based (HB) programs are as effective as ID programs. The purpose of this study was to compare the effects of 16 weeks of ID exercise versus a HB exercise program for HD patients. A total of 46 patients were randomly assigned to the ID group (n = 24) or HB group (n = 22). They completed a 16-week combined exercise program 3 times/week. We measured physical activity level, physical functioning, depression level, and health-related quality of life at baseline and after 16 weeks. A significant time effect was found in both groups for the physical activity level (p = 0.012). There was also a significant group–time interaction effect for the one-leg standing test (OLST) (p = 0.049) and a significant time effect for the Short Physical Performance Battery (p = 0.013), timed up-and-go test (p = 0.005), sit-to-stand-10 (p = 0.027), right and left hand handgrip (p = 0.044, p < 0.001), one-heel left leg raise (p = 0.019), and 6-minute walking (p = 0.006), depression (p = 0.017). HRQoL remained unchanged. There was no difference between the two interventions on the tested outcomes (besides OLST). Both interventions were associated with positive changes of the physical activity levels and physical function.

Chronic kidney disease (CKD) patients undergoing hemodialysis (HD) present a progressive functional deterioration, poor health-related quality of life (HRQoL), and low levels of physical activity compared to their healthy age-matched counterparts^{1,2}. In addition, this population often presents symptoms of depression and anxiety^{3–5}. Exercise programs for people with CKD have been implemented since the beginning of 1980s⁶. For optimal benefits, these programs should include a combination of aerobic exercise and strength resistance⁷. The few studies carried out in HD units in Spain have tested different exercise types including strength-resistance⁸, resistance⁹, low intensity endurance training^{10,11}, neuromuscular electrostimulation^{12,13}, and virtual reality¹⁴.

Different exercise modalities have been studied in the literature, but intradialytic (ID) exercise is considered the best approach¹⁵ because adherence to this modality is higher than with other formats¹⁶. Nevertheless, to the best of our knowledge, HD units in Spain do not currently include exercise as part of routine HD treatments, perhaps because of the financial cost associated with ID exercise programs. Thus, home-based (HB) programs

¹Department of Physical Therapy, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain. ²Department of Physical Therapy, Universidad Europea de Valencia, Valencia, Spain. ³Centre for Health, Activity and Rehabilitation Research School of Health Sciences, Queen Margaret University, Musselburgh, UK. ⁴These authors contributed equally: Lucía Ortega-Pérez de Villar, Francisco José Martínez-Olmos, Vicent Benavent-Caballer, Francisco Javier Montañez -Aguilera, Tom Mercer and Eva Segura-Ortí. ^{Exa}e-mail: lucia.ortega@universidadeuropea.es

may be an option that could compensate for these cost-related constraints¹⁷. To our knowledge, only a few studies have applied HB exercise programs. We found a total of twelve HB studies in HD patients^{17–28}: 9 of them were randomized controlled trials^{16–18,23–28}, and only 3^{16–18} implemented a combined HB exercise program comprising both aerobic and strength exercises. Several studies measured physical functioning through physical performance tests but none analyzed the effect of the interventions on physical activity levels.

It is well known that the physical activity levels of patients in maintenance HD are lower than their healthy age-matched counterparts^{29–31}. Sedentary behavior is associated with physical deterioration and usually results in limitations in the performance of the activities of daily living which could lead to disability^{32–34}. This can increase both the number of comorbid conditions presented by patients with HD as well as their mortality risk (especially with cardiovascular problems)³⁵. Thus, it is important to implement interventions to increase the physical activity level of patients with HD.

Therefore, the primary aim of this study was to compare the effects of ID versus HB exercise programs on the physical activity level of patients on maintenance HD. The secondary aims were (i) to compare the effects of ID versus HB exercise on physical function, (ii) HRQoL, (iii) the symptoms of depression, and (iv) on adherence. We hypothesized that the ID program would result in more benefits than the HB exercise program.

Results

Forty-six patients undergoing HD were recruited and randomly allocated into the ID or HB exercise groups. There were 13 dropouts in the ID group and 10 in the HB group (see Fig. 1). Table 1 shows the baseline clinical characteristics and demographics of the study cohort. No significant differences were found between groups at baseline either in demographic or functional tests, indicating the successful randomization of the participants.

The adherence to the exercise programs was 80.8% for the ID exercise group (number of sessions completed P25 = 29-P75 = 42 and number of missed session P25 = 6-P75 = 19) and 53% for the HB group (number of sessions completed P25 = 11 P75 = 37 and number of missed session HB P25 = 3-P75 = 37).

Primary outcomes. Table 2 shows the physical activity values measured via the HAP. There was a significant time effect but a non-significant interaction effect and both groups had increased their physical activity levels by the end of the intervention (ID group pre = 62.4 ± 16.6 , post = 67.3 ± 15.6 ; HB group pre= 51.1 ± 18.1 , post= 54.3 ± 19.3 ; F = 7.642, p = 0.012). Another secondary measure of physical activity showed similar results (PASE results in Table 2).

Both interventions were equally effective at increasing physical activity levels among the participants after 16 weeks of ID or HB exercise, without differences between groups. At baseline the HB group contained 8 individuals with impaired activity (AAS < 53 points), 1 who was moderately active (AAS = 53–74 points), and 3 active patients (AAS > 74 points), whereas at the end of the HB, 5 individuals were moderately active. Regarding the ID group, at baseline 5 individuals had impaired activity, 3 were moderately active, and 3 were active; by the end of the program 4 individuals were moderately active and 5 were active. Both interventions lifted participants from the impaired activity category.

Secondary outcomes. Table 3 shows the values from the physical functioning tests for each group at baseline and after 16 weeks performing a combined exercise program. The results of the two-way ANOVA showed a significant group-time interaction for the OLST (p = 0.049, $\eta_p^2 = 0.189$). The within-group analysis showed significant improvements in the ID group for the OLST (5.9 s, 95%CI [1.42–10.55]; p = 0.013). The time-group interaction was not significant for the STS-10, SPPB, TUG, HG, or 6MWT. However, we observed a significant time effect, indicating that performance improved in both intervention groups.

The values obtained for the CES-D and HRQoL in each group at baseline and after 16 weeks are shown in Table 4. The group–time interaction was not significant for any of the questionnaires. Depression rates improved in both intervention groups and HRQoL components remained unchanged.


Discussion


The purpose of this study was to compare the effect on HD patients of performing an ID versus HB 16-week exercise program. To our knowledge, this is the first HB exercise program devised and tested in Spain. We wanted to discover if, in a Spanish population on HD, performing a HB program improved patient physical activity, physical functioning, and HRQoL and CES-D scores.

The study design tried to implement two different interventions balanced in exercise intensity and volume. Both programs aimed at improving lower limb muscle strength of the most commonly used muscle groups in activities of daily living, although the restricted position for the ID group limited how to perform strengthening exercises, and at HB group was not restricted at all regarding positions to do strength exercises. We tried also to mimic the aerobic component, though ID group cycled while the HB group walked. Sessions per week, exercise volume (sets and repetitions, so as weights lifted) and exercise time was quite similar in both groups.

Increased physical activity levels may result in a better physical condition³. Thus, we believe the increase we found is important and hope it will inspire nephrologists and renal nurses to implement interventions designed to encourage exercise among patients in HD units. A previous study did not find any significant differences between 12 weeks of resistance training versus a group receiving an anabolic steroid (nandrolone) in terms of physical activity outcomes in terms of the AAS³⁶. It is possible that combined exercise for a longer time (16 weeks) had a higher impact on daily physical activity.

In terms of physical function, a significant group-time interaction was found only for the OLST, while the OLST time also increased in the ID group. To our knowledge, ours is the first study to use the OLST to measure physical functioning in a population on HD. The fact that balance improved only in the ID group is surprising because the ID program did not include any exercise that specifically targeted this ability. However, this outcome





.....

may be explained by the improved lower limb muscle activity generally associated with exercise and the higher exercise adherence rate in the ID program³⁷. This result, since is the only functional measure that showed a group per time interaction effect, could also be found by chance.

The impact of exercise programs on the other physical function metrics was not significantly different between groups. Thus, like the physical activity level outcome, the functional level of the participants improved in both programs. The STS-10 results improved from baseline to 16 weeks although we did not achieve the minimal detectable change (MDC) of 8.4 seconds³⁸. The results for the ID group concur with those from previous studies reporting improvements in this test ranging from 2.5 to 5.75 seconds^{8,9,18,39-41}. However, the magnitude of improvement in the HB group was less than in a previous study¹⁸. Compared with these previous studies, our patients required more time at baseline to perform the tests. Moreover, poor adherence in the HB group may have negatively affected our results.

The 6MWT results significantly improved between the baseline and 16 weeks, even though the MDC of 66.3 meters was not achieved³⁸. We detected a similar change in the ID group as in previous studies⁴²⁻⁴⁴. Nevertheless, the improvement in the HB group we achieved was lower than in previous studies^{19,20}, perhaps because these participants had used a pedometer for walking training, thus providing them with direct feedback which could have been a motivational factor. The 6MWT increased in one study²⁸ that implemented walking training in a home-based program. This study ensured the education of the dialysis personnel in the exercise program, who also assisted in the training phase of the trial. Thus, the nursing team could encourage patients to complete the program and this fact could have resulted in increased adherence to exercise.

In agreement with a previous study¹⁸, after 16 weeks of ID or HB training neither the group-time interaction or time significantly affected self-reported HRQoL (KDQoL-36). There was a non-significant physical component

Age (years) Image (beam of the second of the		ID exercise	ID exercise	HB Exercise	HB exercise	
Mean (SD) 62.2 (15.0)65.3 (15.2)59.3 (16.1)61.9 (12.1)Median (min-max)66.5 (45.8-72.3)69 (37-81)57 (46-73)65 (37-78)Time on HD (months)46 (24-61)40.6 (32.7)45 (24-122)89.8 (32.7)Median (P25-P75)46 (24-61)40.6 (32.7)45 (24-122)89.8 (32.7)Sex n (%)115 (32.6)14 (63.6)14 (30.4)Fenale9 (37.5)9 (19.6)8 (36.4)8 (17.4)Weight, (kg)73.6 (13.9)73.6 (13.9)70.5 (17.1)70.5 (17.1)Median (min-max)71.5 (54.5-103)71.5 (54.5-103)67 (49-117)67 (49-117)Height, (cm)1.66 (0.1)1.67 (0.1)1.67 (0.1)1.67 (0.1)1.67 (0.1)Median (min-max)1.66 (1.1)1.67 (1.5-1.8)1.68 (1.5-1.8)1.68 (1.5-1.8)Body mass index (kg/m²)1.66 (0.1)1.67 (0.1)1.67 (0.1)1.67 (0.1)Median (min-max)26.6 (3.7)26.6 (3.7)25.1 (5.3)26.6 (3.7)Abumi (mg/D)26.6 (3.7)26.6 (3.7)23.8 (17.6-37.8)23.8 (17.6-37.8)Abumi (mg/dL)1.603.7 (0.3)3.7 (0.3)3.7 (0.3)Median (min-max)3.6 (2.5-4.2)3.7 (3.3-4.2)3.7 (3.3-4.2)Abumi (mg/D)3.6 (0.4)3.7 (0.3)3.7 (0.3)Median (min-max)7.2 (3.0-12.7)7.2 (3.0-12.7)8.3 (3.1-17.4)Mean (SD)6.7 (3.4)7.9 (3.9)7.9 (3.9)Median (min-max)7.2 (3.0-12.7)7.2 (3.0-12.7)8.3 (3.1-17.4)Mean (Variable					
Median (min-max) 66.5 (45.8-72.3) 69 (37-81) 57 (46-73) 65 (37-78) Time on HD (months) 46 (24-61) 40.6 (32.7) 45 (24-122) 89.8 (32.7) Sex n (%) 5 15 (32.6) 14 (63.6) 14 (30.4) Female 9 (37.5) 9 (19.6) 8 (36.4) 8 (17.4) Weight, (kg) 73.6 (13.9) 73.6 (13.9) 70.5 (17.1) 70.5 (17.1) Median (min-max) 71.5 (54.5-103) 71.5 (54.5-103) 67 (49-117) 67 (49-117) Height, (cm) 1.66 (0.1) 1.66 (0.1) 1.67 (0.1) 1.67 (1.5-1.8) 1.68 (1.5-1.8) 1.68 (1.5-1.8) Body mass index (kg/m²) 1.67 (1.2-1.8) 1.66 (1.2) 2.6 (3.7) 25.1 (5.3) 2.6 (3.7) Mean (SD) 2.6 (2.13-32.9) 2.8 (17.6-37.8) 2.8 (17.6-37.8) 2.8 (17.6-37.8) Albumin (mg/dL) 4 3.6 (2.5-4.2) 3.7 (3.3-4.2) 3.7 (3.3-4.2) Median (min-max) 3.6 (2.5-4.2) 3.6 (2.5-4.2) 3.7 (3.3-4.2) 3.7 (3.3-4.2) Median (min/max) 3.6 (2.5-4.2) 3.6 (2.1-7.4)	Age (years)					
Time on HD (months) Image: Section of the	Mean (SD)	62.2 (15.0)	65.3 (15.2)	59.3 (16.1)	61.9 (12.1)	
Median (P25–P75) 46 (24–61) 40.6 (32.7) 45 (24–122) 89.8 (32.7) Sex n (%) 1 15 (62.5) 15 (32.6) 14 (63.6) 14 (30.4) Female 9 (37.5) 9 (19.6) 8 (36.4) 8 (17.4) Weight, (kg) 73.6 (13.9) 73.6 (13.9) 70.5 (17.1) 70.5 (17.1) Median (min-max) 7.15 (54.5–103) 71.5 (54.5–103) 67 (49–117) 67 (49–117) Height, (cm) 1.66 (0.1) 1.66 (0.1) 1.67 (0.1) 1.67 (0.1) Median (min-max) 1.67 (1.5–1.8) 1.66 (1.5–1.8) 1.68 (1.5–1.8) 1.68 (1.5–1.8) Body mass index (kg/m ²) 1.66 (0.1) 1.67 (0.1) 1.67 (0.3) 2.6.6 (3.7) Median (min-max) 2.6.1 (21.3–32.9) 2.6.1 (21.3–32.9) 2.8.1 (7.6–37.8) 2.8.1 (7.6–37.8) Albumin (mg/dL) Median (min-max) 3.6 (0.4) 3.6 (0.4) 3.7 (0.3) 3.7 (0.3) Median (min-max) 2.6.2 (-2.2) 3.6 (2.5–4.2) 3.7 (3.3–4.2) 3.7 (3.3–4.2) Median (min-max) 2.2 (0.1-2.7) 7.2 (3.0–12.7) 8.3 (3.1–17.4) <td>Median (min-max)</td> <td>66.5 (45.8-72.3)</td> <td>69 (37-81)</td> <td>57 (46-73)</td> <td>65 (37–78)</td>	Median (min-max)	66.5 (45.8-72.3)	69 (37-81)	57 (46-73)	65 (37–78)	
Sex n (%) Normality Normality Normality Normality Male 15 (62.5) 15 (32.6) 14 (63.6) 14 (30.4) Female 9 (37.5) 9 (19.6) 8 (36.4) 8 (17.4) Weight, (kg) 73.6 (13.9) 70.5 (17.1) 70.5 (17.1) Mean (SD) 73.6 (13.9) 73.6 (13.9) 70.5 (17.1) 67 (49–117) Height, (cm) 67 (49–117) 67 (49–117) Height, (cm) 1.66 (0.1) 1.67 (1.5–1.8) 1.68 (1.5–1.8) 1.68 (1.5–1.8) Body mass index (kg/m ²) 1.67 (1.5–1.8) 1.66 (0.1) 1.67 (0.1) Median (min-max) 26.1 (21.3–32.9) 26.1 (21.3–32.9) 23.8 (17.6–37.8) 23.8 (17.6–37.8) Albumin (mg/dL) Mean (SD) 3.6 (0.4) 3.6 (0.4) 3.7 (0.3) 3.7 (0.3) Median (min-max) 3.6 (2.5–4.2) 3.7 (3.3–4.2) 3.7 (3.3–4.2)	Time on HD (months)					
Male 15 (62.5) 15 (32.6) 14 (63.6) 14 (30.4) Female 9 (37.5) 9 (19.6) 8 (36.4) 8 (17.4) Weight, (kg) 73.6 (13.9) 73.6 (13.9) 70.5 (17.1) 70.5 (17.1) Median (min-max) 71.5 (54.5-103) 71.5 (54.5-103) 67 (49-117) 67 (49-117) Height, (cm) 1.66 (0.1) 1.66 (0.1) 1.67 (0.1) 1.67 (0.1) Median (min-max) 1.67 (1.5-1.8) 1.66 (1.5) 1.68 (1.5-1.8) 1.68 (1.5-1.8) Body mass index (kg/m ²⁾ 1.66 (0.1) 1.67 (0.1) 1.67 (0.1) 1.66 (0.7) Mean (SD) 2.6.6 (3.7) 25.1 (5.3) 26.6 (3.7) 23.8 (17.6-37.8) Albumin (mg/dL) Median (min-max) 2.6.1 (21.3-32.9) 23.8 (17.6-37.8) 23.8 (17.6-37.8) Median (min-max) 3.6 (0.4) 3.7 (0.3) 3.7 (0.3) 3.7 (0.3) Median (min-max) 3.6 (2.5-4.2) 3.6 (2.5-4.2) 3.7 (3.3-4.2) 3.7 (3.3-4.2) Median (min-max) 7.2 (3.0-12.7) 7.2 (3.0-12.7) 8.3 (3.1-17.4) 8.3 (3.1-17.4)	Median (P25-P75)	46 (24-61)	40.6 (32.7)	45 (24–122)	89.8 (32.7)	
Female 9 (37.5) 9 (19.6) 8 (36.4) 8 (17.4) Weight, (kg) 73.6 (13.9) 73.6 (13.9) 70.5 (17.1) 70.5 (17.1) Median (min-max) 71.5 (54.5-103) 71.5 (54.5-103) 67 (49-117) 67 (49-117) Height, (cm) 67 (15-1.8) 1.67 (0.1) 1.67 (0.1) 1.67 (0.1) Median (min-max) 1.67 (1.5-1.8) 1.66 (0.1) 1.66 (0.1) 1.66 (0.1) 1.68 (1.5-1.8) Body mass index (kg/m ²) 1.67 (1.5-1.8) 1.67 (1.3-32.9) 25.1 (5.3) 26.6 (3.7) Median (min-max) 26.1 (21.3-32.9) 26.1 (21.3-32.9) 23.8 (17.6-37.8) 23.8 (17.6-37.8) Albumin (mg/dL) 3.7 (0.3) 3.7 (0.3) Median (min-max) 3.6 (2.5-4.2) 3.7 (0.3) 3.7 (0.3) 3.7 (0.3) 3.7 (3.3-4.2) Median (min-max) 7.2 (3.0-12.7) 7.9 (3.9) 7.9 (3.9) 3.6 (2.5-4.2) 3.7 (0.3) 3.3 (3.1-17.4) Mean (SD) 6.7 (3.4) 6.7 (3.4) 7.9 (3.9) 7.9 (3.9) 7.9 (3.9) Mean (SD)	Sex <i>n</i> (%)					
Weight, (kg) No. 1 No. 1 No. 1 No. 1 Mean (SD) 73.6 (13.9) 73.6 (13.9) 70.5 (17.1) 70.5 (17.1) Median (min-max) 71.5 (54.5-103) 71.5 (54.5-103) 67 (49-117) 67 (49-117) Height, (cm) 1.66 (0.1) 1.66 (0.1) 1.67 (1.5-1.8) 1.68 (1.5-1.8) 1.68 (1.5-1.8) Body mass index (kg/m ²) 1.67 (1.5-1.8) 1.67 (1.5-1.8) 1.68 (1.5-1.8) 1.68 (1.5-1.8) Mean (SD) 26.6 (3.7) 26.6 (3.7) 25.1 (5.3) 26.6 (3.7) Median (min-max) 26.1 (21.3-32.9) 26.8 (17.6-37.8) 23.8 (17.6-37.8) Albumin (mg/dL) 3.7 (0.3) Median (min-max) 3.6 (2.5-4.2) 3.6 (2.5-4.2) 3.7 (0.3) Median (min-max) 3.6 (2.5-4.2) 3.6 (2.5-4.2) 3.7 (3.3-4.2) 3.7 (0.3) Median (min-max) 7.2 (3.0-12.7) 7.2 (3.0-12.7) 8.3 (3.1-17.4) 8.3 (3.1-17.4) Mean (SD) 10.8 (0.8) 10.8 (0.8) 10.5 (1.7) 10.5 (1.7) Mean (SD) 10.8 (0.8.1)	Male	15 (62.5)	15 (32.6)	14 (63.6)	14 (30.4)	
Mean (SD) 73.6 (13.9) 73.6 (13.9) 70.5 (17.1) 70.5 (17.1) Median (min-max) 71.5 (54.5-103) 71.5 (54.5-103) 67 (49-117) 67 (49-117) Height, (cm) 1.66 (0.1) 1.66 (0.1) 1.67 (0.1) 1.67 (0.1) Median (min-max) 1.67 (1.5-1.8) 1.67 (1.5-1.8) 1.68 (1.5-1.8) 1.68 (1.5-1.8) Body mass index (kg/m ²) 26.6 (3.7) 26.6 (3.7) 25.1 (5.3) 26.6 (3.7) Median (min-max) 26.1 (21.3-32.9) 26.1 (21.3-32.9) 23.8 (17.6-37.8) 23.8 (17.6-37.8) Albumin (mg/dL) 3.6 (0.4) 3.7 (0.3) 3.7 (0.3) Median (min-max) 3.6 (2.5-4.2) 3.7 (3.3-4.2) 3.7 (3.3-4.2) 3.7 (3.3-4.2) Mean (SD) 3.6 (0.4) 3.6 (2.5-4.2) 3.7 (3.3) 3.7 (3.3) Median (min-max) 7.2 (3.0-12.7) 7.2 (3.0-12.7) 8.3 (3.1-17.4) 8.3 (3.1-17.4) Hemoglobin (g/dL) 10.5 (1.7) 10.5 (1.7) Median (min-max) 10.8 (0.8) 10.8 (0.8) 10.5	Female	9 (37.5)	9 (19.6)	8 (36.4)	8 (17.4)	
Median (min-max) 71.5 (54.5-103) 71.5 (54.5-103) 67 (49-117) 67 (49-117) Height, (cm)	Weight, (kg)	1	1			
Height, (cm) Instrume Instrume Instrume Instrume Mean (SD) 1.66 (0.1) 1.67 (1.5 - 1.8) 1.66 (1.5 - 1.8) 1.68 (1.5 - 1.8) Body mass index (kg/m ²) Instrume Instrume Instrume Instrume Mean (SD) 26.6 (3.7) 25.1 (5.3) 26.6 (3.7) Instrume Median (min-max) 26.1 (21.3 - 32.9) 26.6 (3.7) 25.1 (5.3) 26.6 (3.7) Median (min-max) 26.6 (0.4) 3.6 (0.4) 3.7 (0.3) 3.7 (0.3) Albumin (mg/dL) Mean (SD) 3.6 (0.4) 3.6 (0.5 - 4.2) 3.7 (0.3) 3.7 (0.3) Median (min-max) 3.6 (2.5 - 4.2) 3.6 (0.5 - 4.2) 3.7 (0.3) 3.7 (0.3) 3.7 (0.3) Median (min-max) 3.6 (2.5 - 4.2) 3.6 (0.5 - 4.2) 3.7 (3.3 - 4.2) 3.7 (0.3) 3.7 (0.3) Mean (SD) 6.7 (3.4) 6.7 (3.4) 7.9 (3.9) 7.9 (3.9) 7.9 (3.9) Mean (SD) 10.8 (0.8) 10.8 (0.8) 10.5 (1.7) 10.5 (1.7) Mean (SD) 10.8 (0.8) 10.8 (0.8) 10.5 (1.7)	Mean (SD)	73.6 (13.9)	73.6 (13.9)	70.5 (17.1)	70.5(17.1)	
Mean (SD) 1.66 (0.1) 1.67 (0.1) 1.67 (0.1) Median (min-max) 1.67 (1.5-1.8) 1.67 (1.5-1.8) 1.68 (1.5-1.8) 1.68 (1.5-1.8) Body mass index (kg/m ²) Mean (SD) 26.6 (3.7) 26.6 (3.7) 25.1 (5.3) 26.6 (3.7) Median (min-max) 26.1 (21.3-32.9) 26.1 (21.3-32.9) 23.8 (17.6-37.8) 23.8 (17.6-37.8) Albumin (mg/dL) Mean (SD) 3.6 (0.4) 3.6 (0.4) 3.7 (0.3) 3.7 (0.3) Median (min-max) 3.6 (2.5-4.2) 3.6 (2.5-4.2) 3.7 (3.3-4.2) 3.7 (0.3) Median (min-max) 3.6 (2.5-4.2) 3.6 (2.5-4.2) 3.7 (3.3-4.2) 3.7 (0.3) Mean (SD) 6.7 (3.4) 7.9 (3.9) 7.9 (3.9) 7.9 (3.9) Mean (SD) 6.7 (3.4) 7.9 (3.9) 7.9 (3.9) 8.3 (3.1-17.4) Mean (SD) 10.8 (0.8) 10.8 (0.8) 10.5 (1.7) 10.5 (1.7) Mean (SD) 10.8 (0.8) 10.8 (0.8) 10.5 (1.7) 10.5 (1.7) Mean (SD) 10.8 (9.4-12.5) 10.8 (9.4-12.5) 11.1 (6.6-12.8) 11.1 (6.6-12.8)	Median (min-max)	71.5 (54.5–103)	71.5 (54.5-103)	67 (49–117)	67 (49–117)	
Median (min-max) 1.67 (1.5-1.8) 1.67 (1.5-1.8) 1.68 (1.5-1.8) 1.68 (1.5-1.8) Body mass index (kg/m²) Mean (SD) 26.6 (3.7) 26.6 (3.7) 25.1 (5.3) 26.6 (3.7) Median (min-max) 26.1 (21.3-32.9) 26.1 (21.3-32.9) 23.8 (17.6-37.8) 23.8 (17.6-37.8) Albumin (mg/dL) Mean (SD) 3.6 (0.4) 3.7 (0.3) 3.7 (0.3) Median (min-max) 3.6 (2.5-4.2) 3.6 (2.5-4.2) 3.7 (0.3) 3.7 (3.3-4.2) Median (min-max) 3.6 (2.5-4.2) 3.6 (2.5-4.2) 3.7 (0.3) 3.7 (3.3-4.2) Median (min-max) 3.6 (2.5-4.2) 3.6 (2.5-4.2) 3.7 (3.3-4.2) 3.7 (3.3-4.2) Creatinine (mg/dL) Mean (SD) 6.7 (3.4) 6.7 (3.4) 7.9 (3.9) 7.9 (3.9) Median (min-max) 7.2 (3.0-12.7) 7.2 (3.0-12.7) 8.3 (3.1-17.4) 8.3 (3.1-17.4) Hemoglobin (g/dL) I0.8 (0.8) 10.8 (0.8) 10.5 (1.7) 10.5 (1.7) Median (min-max) 10.8 (0.8) 10.8 (0.8) 10.5 (1.7) 10.5 (1.7) Median (min-max) 10.8 (0.8) 10.5 (1	Height, (cm)	1	1			
International problem internation problem international problem international problem internation	Mean (SD)	1.66 (0.1)	1.66 (0.1)	1.67 (0.1)	1.67 (0.1)	
Mean (SD) 26.6 (3.7) 26.6 (3.7) 25.1 (5.3) 26.6 (3.7) Median (min-max) 26.1 (21.3-32.9) 26.1 (21.3-32.9) 23.8 (17.6-37.8) 23.8 (17.6-37.8) Albumin (mg/dL) Mean (SD) 3.6 (0.4) 3.6 (0.4) 3.7 (0.3) 3.7 (0.3) Median (min-max) 3.6 (2.5-4.2) 3.6 (2.5-4.2) 3.7 (3.3-4.2) 3.7 (3.3-4.2) Creatinine (mg/dL) Mean (SD) 6.7 (3.4) 6.7 (3.4) 7.9 (3.9) 7.9 (3.9) Median (min-max) 7.2 (3.0-12.7) 7.2 (3.0-12.7) 8.3 (3.1-17.4) 8.3 (3.1-17.4) Hemoglobin (g/dL) Mean (SD) 10.8 (0.8) 10.5 (1.7) 10.5 (1.7) Median (min-max) 10.8 (9.4-12.5) 10.8 (9.4-12.5) 11.1 (6.6-12.8) 11.1 (6.6-12.8) CKD Diagnosis I 10.8 (9.4-12.5) 11.1 (6.6-12.8) 11.1 (6.6-12.8) Diabetes mellitus 3 3 0 0 Polycystosis 1 1 1 1 Iupus 3 3 0 0 Nephroangiosclerosis 2	Median (min-max)	1.67 (1.5–1.8)	1.67 (1.5-1.8)	1.68 (1.5-1.8)	1.68 (1.5-1.8)	
Median (min-max) 26.1 (21.3-32.9) 26.1 (21.3-32.9) 23.8 (17.6-37.8) 23.8 (17.6-37.8) Albumin (mg/dL)	Body mass index (kg/m ²)		1	l.		
Albumin (mg/dL) 3.6 (0.4) 3.6 (0.4) 3.7 (0.3) 3.7 (0.3) Mean (SD) 3.6 (0.4) 3.6 (0.4) 3.7 (0.3) 3.7 (0.3) Median (min-max) 3.6 (2.5-4.2) 3.6 (2.5-4.2) 3.7 (3.3-4.2) 3.7 (3.3-4.2) Creatinine (mg/dL) 6.7 (3.4) 6.7 (3.4) 7.9 (3.9) 7.9 (3.9) Median (min-max) 7.2 (3.0-12.7) 7.2 (3.0-12.7) 8.3 (3.1-17.4) 8.3 (3.1-17.4) Hemoglobin (g/dL) 8.3 (3.1-17.4) Mean (SD) 10.8 (0.8) 10.8 (0.8) 10.5 (1.7) 10.5 (1.7) Median (min-max) 10.8 (9.4-12.5) 11.1 (6.6-12.8) 11.1 (6.6-12.8) CKD Diagnosis 1 1.1 (6.6-12.8) Diabetes mellitus 3 3 5 5 Glomerulonephritis 4 4 8 8 Lupus 3 3 0 0 Nephroangiosclerosis 2 2 1 1 Pyelonephritis 1 1 1 1 High blood pressure	Mean (SD)	26.6 (3.7)	26.6 (3.7)	25.1 (5.3)	26.6 (3.7)	
Mean (SD) 3.6 (0.4) 3.6 (0.4) 3.7 (0.3) 3.7 (0.3) Median (min-max) 3.6 (2.5-4.2) 3.6 (2.5-4.2) 3.7 (3.3-4.2) 3.7 (3.3-4.2) Creatinine (mg/dL) Median (min-max) 6.7 (3.4) 6.7 (3.4) 7.9 (3.9) 7.9 (3.9) Median (min-max) 7.2 (3.0-12.7) 7.2 (3.0-12.7) 8.3 (3.1-17.4) 8.3 (3.1-17.4) Hemoglobin (g/dL) Mean (SD) 10.8 (0.8) 10.8 (0.8) 10.5 (1.7) 10.5 (1.7) Median (min-max) 10.8 (9.4-12.5) 10.8 (9.4-12.5) 11.1 (6.6-12.8) 11.1 (6.6-12.8) CKD Diagnosis Joabetes mellitus 3 3 5 5 Glomerulonephritis 4 4 8 8 11.1 (6.6-12.8) Iupus 3 3 0 0 0 0 Polycystosis 1 1 0 0 0 0 0 Nephroangiosclerosis 2 2 1 1 1 1 1 1 1 1 1 1 1	Median (min-max)	26.1 (21.3-32.9)	26.1 (21.3-32.9)	23.8 (17.6-37.8)	23.8 (17.6-37.8)	
Median (min-max) 3.6 (2.5-4.2) 3.6 (2.5-4.2) 3.7 (3.3-4.2) 3.7 (3.3-4.2) Creatinine (mg/dL) Mean (SD) 6.7 (3.4) 6.7 (3.4) 7.9 (3.9) 7.9 (3.9) Median (min-max) 7.2 (3.0-12.7) 7.2 (3.0-12.7) 8.3 (3.1-17.4) 8.3 (3.1-17.4) Hemoglobin (g/dL) Mean (SD) 10.8 (0.8) 10.8 (0.8) 10.5 (1.7) 10.5 (1.7) Median (min-max) 10.8 (9.4-12.5) 10.8 (9.4-12.5) 11.1 (6.6-12.8) 11.1 (6.6-12.8) Median (min-max) 10.8 (9.4-12.5) 10.8 (9.4-12.5) 11.1 (6.6-12.8) 11.1 (6.6-12.8) CKD Diagnosis J 3 5 5 5 Glomerulonephritis 4 4 8 8 1 Lupus 3 3 0 0 0 0 Nephroangiosclerosis 2 2 1 1 1 1 Pyelonephritis 1 1 1 1 1 1 1 High blood pressure 3 3 0 0	Albumin (mg/dL)		1	l.		
Creatinine (mg/dL) 6.7 (3.4) 6.7 (3.4) 7.9 (3.9) 7.9 (3.9) Median (min-max) 7.2 (3.0–12.7) 7.2 (3.0–12.7) 8.3 (3.1–17.4) 8.3 (3.1–17.4) Hemoglobin (g/dL) 8.3 (3.1–17.4) 8.3 (3.1–17.4) Mean (SD) 10.8 (0.8) 10.8 (0.8) 10.5 (1.7) 10.5 (1.7) Median (min-max) 10.8 (9.4–12.5) 10.8 (9.4–12.5) 11.1 (6.6–12.8) 11.1 (6.6–12.8) CKD Diagnosis 10.8 (9.4–12.5) 10.8 (9.4–12.5) 11.1 (6.6–12.8) 11.1 (6.6–12.8) CKD Diagnosis 3 5 5 5 Glomerulonephritis 4 4 8 8 Lupus 3 3 0 0 Polycystosis 1 1 0 0 Nephroangiosclerosis 2 2 1 1 High blood pressure 3 3 0 0 Traumatic kidney injury 0 2 2 2 Others 7 7 5 5	Mean (SD)	3.6 (0.4)	3.6 (0.4)	3.7 (0.3)	3.7 (0.3)	
Mean (SD) 6.7 (3.4) 6.7 (3.4) 7.9 (3.9) 7.9 (3.9) Median (min-max) 7.2 (3.0–12.7) 7.2 (3.0–12.7) 8.3 (3.1–17.4) 8.3 (3.1–17.4) Hemoglobin (g/dL) Mean (SD) 10.8 (0.8) 10.8 (0.8) 10.5 (1.7) 10.5 (1.7) Median (min-max) 10.8 (0.8) 10.8 (0.8) 10.5 (1.7) 10.5 (1.7) Median (min-max) 10.8 (9.4–12.5) 10.8 (9.4–12.5) 11.1 (6.6–12.8) 11.1 (6.6–12.8) CKD Diagnosis J 10.8 (9.4–12.5) 10.8 (9.4–12.5) 11.1 (6.6–12.8) 11.1 (6.6–12.8) CKD Diagnosis J 3 5 5 5 Glomerulonephritis 4 4 8 8 1 Lupus 3 3 0 0 0 Polycystosis 1 1 1 1 1 Pyelonephritis 1 1 1 1 1 1 Hypolocod pressure 3 3 0 0 0 1 1 1 1	Median (min-max)	3.6 (2.5-4.2)	3.6 (2.5-4.2)	3.7 (3.3-4.2)	3.7 (3.3-4.2)	
Median (min-max) 7.2 (3.0-12.7) 7.2 (3.0-12.7) 8.3 (3.1-17.4) 8.3 (3.1-17.4) Hemoglobin (g/dL) Mean (SD) 10.8 (0.8) 10.8 (0.8) 10.5 (1.7) 10.5 (1.7) Median (min-max) 10.8 (0.8) 10.8 (9.4-12.5) 11.1 (6.6-12.8) 11.1 (6.6-12.8) CKD Diagnosis 10.8 (9.4-12.5) 10.8 (9.4-12.5) 11.1 (6.6-12.8) 11.1 (6.6-12.8) CKD Diagnosis 3 5 5 5 Glomerulonephritis 4 4 8 8 Lupus 3 3 0 0 Polycystosis 1 1 0 0 Nephroangiosclerosis 2 2 1 1 Pyelonephritis 1 1 1 1 High blood pressure 3 3 0 0 Traumatic kidney injury 0 0 2 2 Others 7 7 5 5	Creatinine (mg/dL)		1	l.		
Hemoglobin (g/dL) 10.8 (0.8) 10.8 (0.8) 10.5 (1.7) 10.5 (1.7) Mean (SD) 10.8 (0.8) 10.8 (0.4-12.5) 11.1 (6.6-12.8) 11.1 (6.6-12.8) Median (min-max) 10.8 (9.4-12.5) 10.8 (9.4-12.5) 11.1 (6.6-12.8) 11.1 (6.6-12.8) CKD Diagnosis 5 5 5 5 Diabetes mellitus 3 3 5 5 Glomerulonephritis 4 4 8 8 Lupus 3 3 0 0 Polycystosis 1 1 0 0 Nephroangiosclerosis 2 2 1 1 Pyelonephritis 1 1 1 1 High blood pressure 3 3 0 0 Traumatic kidney injury 0 0 2 2 Others 7 7 5 5	Mean (SD)	6.7 (3.4)	6.7 (3.4)	7.9 (3.9)	7.9 (3.9)	
Mean (SD) 10.8 (0.8) 10.8 (0.8) 10.5 (1.7) 10.5 (1.7) Median (min-max) 10.8 (9.4-12.5) 10.8 (9.4-12.5) 11.1 (6.6-12.8) 11.1 (6.6-12.8) CKD Diagnosis T T 10.8 (9.4-12.5) 11.1 (6.6-12.8) 11.1 (6.6-12.8) Diabetes mellitus 3 3 5 5 Glomerulonephritis 4 4 8 8 Lupus 3 3 0 0 Polycystosis 1 1 0 0 Nephroangiosclerosis 2 2 1 1 Pyelonephritis 1 1 1 1 High blood pressure 3 3 0 0 Traumatic kidney injury 0 0 2 2 Others 7 7 5 5	Median (min-max)	7.2 (3.0–12.7)	7.2 (3.0–12.7)	8.3 (3.1-17.4)	8.3 (3.1–17.4)	
Median (min-max) 10.8 (9.4-12.5) 10.8 (9.4-12.5) 11.1 (6.6-12.8) 11.1 (6.6-12.8) CKD Diagnosis 3 3 5 5 Diabetes mellitus 3 3 5 5 Glomerulonephritis 4 4 8 8 Lupus 3 3 0 0 Polycystosis 1 1 0 0 Nephroangiosclerosis 2 2 1 1 Pyelonephritis 1 1 1 1 High blood pressure 3 3 0 0 Traumatic kidney injury 0 0 2 2 Others 7 7 5 5	Hemoglobin (g/dL)	1	1	l.		
CKD Diagnosis 3 3 5 5 Diabetes mellitus 3 3 5 5 Glomerulonephritis 4 4 8 8 Lupus 3 3 0 0 Polycystosis 1 1 0 0 Nephroangiosclerosis 2 2 1 1 Pyelonephritis 1 1 1 1 High blood pressure 3 3 0 0 Traumatic kidney injury 0 2 2 2 Others 7 7 5 5 Charlson comorbidity score	Mean (SD)	10.8 (0.8)	10.8 (0.8)	10.5 (1.7)	10.5 (1.7)	
Diabetes mellitus 3 3 5 5 Glomerulonephritis 4 4 8 8 Lupus 3 3 0 0 Polycystosis 1 1 0 0 Nephroangiosclerosis 2 2 1 1 Pyelonephritis 1 1 1 1 High blood pressure 3 0 0 0 Traumatic kidney injury 0 2 2 2 Others 7 7 5 5 Charlson comorbidity score	Median (min-max)	10.8 (9.4–12.5)	10.8 (9.4–12.5)	11.1 (6.6–12.8)	11.1 (6.6–12.8)	
Glomerulonephritis 4 4 8 8 Lupus 3 3 0 0 Polycystosis 1 1 0 0 Nephroangiosclerosis 2 2 1 1 Pyelonephritis 1 1 1 1 High blood pressure 3 0 0 0 Traumatic kidney injury 0 0 2 2 Others 7 7 5 5 Charlson comorbidity score	CKD Diagnosis	1	1	I		
Lupus 3 3 0 0 Polycystosis 1 1 0 0 Nephroangiosclerosis 2 2 1 1 Pyelonephritis 1 1 1 1 High blood pressure 3 3 0 0 Traumatic kidney injury 0 0 2 2 Others 7 5 5 5	Diabetes mellitus	3	3	5	5	
Polycystosis1100Nephroangiosclerosis2211Pyelonephritis1111High blood pressure3300Traumatic kidney injury0022Others7755Charlson comorbidity score </td <td>Glomerulonephritis</td> <td>4</td> <td>4</td> <td>8</td> <td>8</td>	Glomerulonephritis	4	4	8	8	
Nephroangiosclerosis2211Pyelonephritis1111High blood pressure3300Traumatic kidney injury0022Others7755Charlson comorbidity score	Lupus	3	3	0	0	
Pyelonephritis 1 1 1 High blood pressure 3 3 0 0 Traumatic kidney injury 0 0 2 2 Others 7 7 5 5 Charlson comorbidity score - - -	Polycystosis	1	1	0	0	
High blood pressure 3 3 0 0 Traumatic kidney injury 0 0 2 2 Others 7 7 5 5 Charlson comorbidity score	Nephroangiosclerosis	2	2	1	1	
Traumatic kidney injury 0 0 2 2 Others 7 7 5 5 Charlson comorbidity score	Pyelonephritis	1	1	1	1	
Others 7 7 5 5 Charlson comorbidity score	High blood pressure	3	3	0	0	
Charlson comorbidity score	Traumatic kidney injury	0	0	2	2	
	Others	7	7	5	5	
Mean (SD) 6.6 (2.8) 6.6 (2.8) 6.0 (2.0) 6.0 (2.0)	Charlson comorbidity score	1	1	1		
	Mean (SD)	6.6 (2.8)	6.6 (2.8)	6.0 (2.0)	6.0 (2.0)	
Median (min-max) 7 (1-12) 7 (1-12) 6 (3-10) 6 (3-10)	Median (min-max)	7 (1-12)	7 (1-12)	6 (3-10)	6 (3-10)	

Table 1. Baseline clinical characteristics and demographic data (n = 46). CKD: chronic kidney disease; SD: standard deviation. Baseline data comparison between intention to treat [ID (n = 24) and HB (n = 22)] or per-protocol groups [ID (n = 11) and HB (n = 12)] with the Mann-Whitney and Chi squared test showed no significant differences.

.....

improvement over time. Other studies that evaluated the HRQoL via the SF-36 also revealed inconsistent results, perhaps because of the different exercise program durations, the variety and intensity of exercise types used, and the different characteristics of the participants in each study.

Although we did not find significant mental composite results in this study using the KDQoL, the CES-D-time factor did significantly change (p = 0.017). Previous studies measuring depression with others question-naires (such as the *Hospital Anxiety and Depression scale*^{21,45} or the *Beck Depression Inventory*^{26,45}) also found a significant improvement in this variable after exercise.

Participants and clinical researches described a range of barriers to implement the exercise program to explain the low rate response and high dropout rate. Primary barriers for patients were lack of prior knowledge about safety and benefits in exercise programs, fear of injuries during exercise fatigue or symptoms of weakness, and lack of interest or motivation, all of which have been described in previous studies^{15,46}. These studies also describe that if the professional responsible for the exercise program is not routinely treating the HD patients could also be a barrier to participate in exercise programs, so as the lack of explicit nurse support to encourage the exercise program implementation.

		Mean \pm standard deviation		Analysis of variance			
Variable	Group	Baseline	After 16 weeks	(group \times time), <i>p</i> -value	Effect size	Analysis of variance (time), p-value	Effect size
HAP AAS (points) Mean (SD)	ID	62.4 (16.6)	67.3 (15.6)	F=0.356, 0.557	0.017	F = 7.642, 0.012	0.267
	HB	51.1 (18.1)	54.3 (19.3)				
Maria (CD)	ID	76.4 (8.2)	80 (8.5)	F=1.501, 0.234	0.067	F=3.890, 0.062	0.156
	HB	70.8 (11.6)	71 (15)				
PASE (points) Mean (SD)	ID	112.1 (113.7)	138.6 (113.1)	F=0.041, 0.842	0.002	F=15.642, 0.001	0.427
	HB	59.4 (39.9)	83.4 (53.1)				

Table 2. Mixed model of repeated measures for patient physical activity levels. HAP: Human Activity Profile questionnaire; MAS: the number assigned to the activity with the highest oxygen consumption requirement on the HAP questionnaire that the patient still performs; ASS: the adjusted activity score is the difference between the MAS and the number of activities with lower scores (less demanding tasks) on the HAP questionnaire that the participant has stopped performing; PASE: Physical Activity Scale for Elderly. Baseline data comparison between ID (n = 11) and HB (n = 12) with the Mann-Whitney test showed no significant differences.

		Mean \pm standard deviation		Analysis of		Analysis of	
Variable	Group	Baseline	After 16 weeks	variance (group × time), <i>p</i> -value	Effect size	variance (time), <i>p</i> -value	Effect size
STS-10 (seconds)	ID	25.4 (10.6)	22.3 (7.2)	F=0.726, 0.404	0.035	F=5.678, 0.027	0.221
Mean (SD)	HB	25 (10.7)	23.6 (8)				
SPPB (points) Mean	ID	10.6 (1.43)	11 (1.6)	E	0.030	F=7.433, 0.013	0.261
(SD)	HB	10.1 (2.3)	10.8 (2.1)	F = 0.643, 0.432			
OLST (seconds)	ID	12 (14.1)	17.9 (18.4)	E 4 421 0 040	0.189	F=2.829, 0.109	0.130
Mean (SD)	HB	17.2 (19.4)	16.6 (19.8)	F=4.421, 0.049			
TUG (seconds)	ID	7.9 (1.7)	7.6 (1.6)	F=0.405, 0.531	0.019	F=9.717, 0.005	0.316
Mean (SD)	HB	9.5 (2.5)	9.1 (2.2)				
STS-60 (repetitions)	ID	19.7 (7.4)	23.6 (8.2)	F=3.911, 0.062	0.164	F=1.795, 0.195	0.082
Mean (SD)	HB	21.6 (7.7)	20.8 (3.7)				
HG R hand (Kg)	ID	27.8 (11.8)	30 (9.4)	F=0.546, 0.468	0.025	F=4.577, 0.044	0.179
Mean (SD)	HB	29.3 (11.7)	30.3 (11.1)				
HG L hand (Kg) Mean (<i>SD</i>)	ID	26.6 (9.7)	28.7 (9.6)	F=2.061, 0.166	0.089	F=18.212, 0.000	0.464
	HB	25.8 (11.5)	26.9 (10.7)				
One-Heel Raise R Leg (repetitions) Mean (SD)	ID	23.3 (2.5)	23.6 (3.6)	F=0.000, 0.995	0.000	F=0.144, 0.709	0.008
	НВ	18.5 (9.2)	18.9 (9.4)				
One-Heel Raise L leg (repetitions) Mean (SD)	ID	21.6 (4.8)	24.7 (1)	F=0.011, 0.919	0.001	F=6.862, 0.019	0.314
	НВ	17.3 (10.1)	20.1 (9.5)				
6MWT (meters) Mean (<i>SD</i>)	ID	410.7 (107.9)	436.2 (100.5)	F=0.108, 0.745	0.005	F=9.314, 0.006	0.307
	НВ	360.7 (126.7)	381.2 (96.2)				

Table 3. Mixed model of repeated measures for the physical functioning tests. STS: the sit-to-stand test; SPPB: Short Physical Performance Battery; OLST: One-leg standing test; TUG: timed up-and-go test; HG: handgrip strength; 6MWT: 6 minutes walking test. Baseline data comparison between ID (n = 11) and HB (n = 12) with the Mann-Whitney test showed no significant differences.

In our study, the HB participants reported that they completed only 53% of the proposed sessions and it was very difficult to convince them to exercise on their own. We found that patients did not undertake the exercise as suggested and did not implement the program in their life routine. We implemented several strategies to try to improve adherence, but none were very successful. Our HB exercise adherence rate was similar to that reported in a previous study in which the HB group completed 58% of the sessions (using a pedometer)²⁴, while adherence in a study by Koh *et al.* was $71\% \pm 13\%$ (using a diary)²³. This fact underscores the essential importance of HD unit nurses and nephrologists as a means to identify and overcome barriers to exercise. In our study, the fact that the physical therapist was external to the unit was a previously described barrier⁴⁶. Even though adherence was low, we observed an improvement in the physical condition of all the patients when they participated in a HB exercise program.

Study Limitations

Although the findings of this study are positive for both the ID and HB groups, some limitations should be acknowledged. We had a high number of dropouts in both groups and some participants did not want to exercise in the group to which they were randomly allocated: the majority preferred the ID exercise training format. Most of the participants from the HB group did not have support at home and were not supervised or supported

		Mean \pm standard deviation		Analysis of		Analysis of	
Variable	Group	Baseline	After 16 weeks	variance (group × time), <i>p</i> -value	Effect size	variance (time), <i>p</i> -value	Effect size
CES-D (points)	ID	15.5 (13.2)	9.2 (8.7)	F=3.370, 0.081	0.138	F=6.772, 0.017	0.244
Mean (SD)	HB	15.6 (9.9)	14.5 (8.1)				
Symptoms and	ID	83.9 (12.5)	87.7 (11.3)	F=2.375, 0.138	0.102	F=0.738, 0.400	0.034
problems list (points) Mean (SD)	НВ	81.9 (10.7)	80.9 (12.4)				
Burden of kidney disease (points) Mean (SD)	ID	51.7 (29.1)	51.7 (31)	F=0.163, 0.691	0.008	F=0.163, 0.691	0.008
	НВ	40.1 (15.9)	43.2 (22.7)				
Effects of kidney	ID	73.6 (16.8)	65.3 (23.9)	F=0.392, 0.538	0.018	F=2.625, 0.120	0.111
disease on daily life (points) Mean (SD)	НВ	78.6 (19.1)	75 (21.2)				
Physical component summary (points) Mean (SD)	ID	42.0 (10.4)	45.7 (11.2)	F=1.172, 0.291	0.053	F=2.865, 0.105	0.120
	НВ	40.9 (8.6)	41.8 (12.8)				
Mental component summary (points) Mean (SD)	ID	49.9 (9.5)	50.3 (8.1)	F=0.772, 0.390	0.035	F=1.177, 0.290	0.053
	НВ	47 (10.3)	49.9 (11.1)				

Table 4. Mixed-model of repeated measures for depression and health-related quality of life. CES-D: Center for Epidemiologic Studies Depression scale.

by a relative. The only motivational support that they had was when the physical therapist approached them. Moreover, the difficulty level of the strength exercises in the ID group may have been insufficient, even though we measured the 10 repetition maximum every two weeks to ensure their resistance training progression.

Methods

Study design. This was a randomized controlled clinical trial. Eligible participants were randomly assigned either to the ID or HB exercise group. The exercise program lasted 16 weeks and the patient metrics were recorded at baseline and after the intervention.

Participants. The study participants were recruited from two HD units in Valencia (Spain) and were assessed for eligibility by the consulting nephrologist at each unit. For inclusion the patients had to have a stable medical condition and have been receiving HD therapy for at least 3 months. The exclusion criteria were as follows: (a) myocardial infarction in the 6 weeks prior; (b) cardiovascular disease that could worsen with exercise; (c) above the knee amputation without a prothesis; (d) cerebral vascular disease; (e) musculoskeletal and respiratory disorders that might worsen with exercise; and (f) inability to complete functional testing.


This research was approved by the Ethics Committee at the *Hospital Universitario Doctor Peset* in Valencia (Spain; registration number 1/15). Participants provided their written informed consent to participation. This study respected the fundamental principle set out in the Declaration of Helsinki. It met the requirements set out in legislation in accordance with the Data Protection Act. This study was registered at Clinical Trials (NCT02832440; date of registration 08/07/2016).

Participants were randomized by an external investigator in blocks, 4 codes per block, based on age and sex simultaneously, either into the ID or HB group using the www.randomization.com webpage. The allocation was concealed and the researchers performing the assessments were blinded to the random assignment throughout the whole study period.

Intervention and adherence. Both the ID and the HB exercise interventions lasted 16 weeks and are detailed in Fig. 2. Progression was achieved by increasing sets, from 1 to 3, 10 repetitions per set, and load was adapted every 2 weeks after the 10RM test, so that it progressed from 1 kg to 17 kg in some cases. We used ankle cuffs of different weights (1 to 4.5 kg) and elastic bands of increased resistance. In the ID we used the cycle ergometer Mottomed Letto to work the aerobic part (10 to 30 minutes), while the HB were instructed to walk in their normal speed from 15 to 30 minutes. Intensity was adjusted by the Borg Rating of Perceived Exertion Scale at level between 12 and 15. The programs were elaborated by a physiotherapist specializing in therapeutic exercise and aimed to work similar lower-limb muscle groups. Treatment adherence was defined as the number of sessions performed divided by the number of sessions offered, multiplied by 100.

Outcome measurements and tools. Patient clinical and anthropometric data were collected. Physical function was assessed with a battery of functional tests at baseline and after 16 weeks. Physical therapists who were blinded to the individuals' allocation assessed the participants immediately before their HD session. To standardize the procedure, we followed a previous study that developed a detailed script for all the functional tests⁴⁷.

As primary outcome we evaluated patient physical activity levels using the *Human Activity Profile* (HAP) questionnaire which has been validated in populations with CKD³. The HAP comprises a list of 94 activities each assigned a number relating to the vigorousness of the task and the participants must report whether they still do this activity, no longer perform the activity, or never did the activity. The HAP assesses the maximal activity score



HD: Hemodialvsis: PT: Physical therapist

Figure 2. The exercise intervention completed by both the intradialytic and home-based trial groups. HD: Hemodialysis; PT: Physical therapist.

(MAS; the number assigned to the activity with the highest oxygen consumption requirement that the patient still performs) and the adjusted activity score (ASS; the difference between the MAS and the number of activities with lower scores—i.e., less demanding tasks—that the participant has stopped performing). Depending on the AAS, individuals can be classified as having impaired activity (AAS < 53), being moderately active (AAS = 53–74), or as active (AAS > 74)⁴⁸. This questionnaire, especially the AAS, has a high test-retest reliability in this population (MAS intraclass correlation coefficient [ICC] = 0.76; ICC ASS = 0.92)⁴⁹.

Secondary outcomes. Prior to the first weekly HD session, participants performed the Short Physical Performance Battery (SPPB), one-leg standing test (OLST), and timed up-and-go (TUG) test. The SPPB is a battery of functional tests that assesses balance in three different positions (side-by-side, semi-tandem and tandem) for 10 seconds each; gait speed in 4 meters at normal pace; and ability to stand up from a chair 5 repetitions. The score ranges from 0 to 12. The OLST measured the time that each participant could keep a one-leg balance position with eyes open and allowing free movement of the arms. The participants were given 3 trials to try to achieve 45 seconds. The TUG measures the best time of two consecutive trials in standing up from a chair, walking 3 meters, turn back and sit down again. During the second weekly HD session, the sit-to-stand 10/60 (STS-10/60) one-leg heel raise (OLHR), and handgrip strength (HG). The STS-10 measures the time required to complete 10 consecutive full stands from a sitting position, and the STS-60 measured the number of repetitions of sitting down on and getting up from a chair achieved in 60 seconds. The OLHR measures the functional strength of the triceps surae muscle in each leg. The handgrip strength was used to measure the amount of strength developed by each hand, three consecutive repetitions were recorded and the highest peak force was recorded. Finally, in the third weekly HD session the 6-minute walking test (6MWT) was performed and assess the longest distance that a patient can walk during 6 minutes, using any ambulation aid if required. Further detail of the measuring protocol, so as the reliability of all these tests has been reported in previous studies (ICC = 0.83-0.97)^{38,50}.

To evaluate the physical activity level, the participants also completed the *Physical Activity Scale for Elderly* (PASE) questionnaire which has been validated a population with CKD³. The PASE assesses the time spent in the week prior doing specific activities commonly performed by elderly individuals. The total score is recorded as the sum of the amount of time that the person spent on each activity (hours per week) multiplied by the weight assigned to each activity⁵¹.

To assess the symptoms of depression, the participants completed the *Center for Epidemiologic Studies Depression* (CES-D) scale, which comprises 20 questions about depressed mood. Individuals respond to the CES-D by rating the frequency with which they experienced each mood in the week prior on scale ranging from 0 to 3. The total score ranges from 0 to 60 points with higher scores indicating the presence of more symptoms of depression. Participants undergoing HD with a score of 18 or more points were considered at risk for depression⁵².

To assess HRQoL in patients with CKD, we used the *Kidney Disease Quality of Life-Short Form* (KDQoL-36) survey which comprises 36 items that describe the individual's perception of their health in the 4 weeks prior. It is divided into five categories: (i) symptoms/problems; (ii) kidney disease burden; (iii) kidney disease effects; (iv) physical components; and (v) mental components. The maximum score per category is 100 points and higher scores indicate better perceived health status⁵³. This Spanish version of the questionnaire has been validated and is reliable, with ICCs ranging from 0.62 to 0.77 for each dimension⁴.

Sample size calculation. The sample size was calculated by detecting changes in physical activity using the average AAS HAP score. Taking previous data from an exercise-based intervention in HD patients into account⁵⁴, and considering an alpha error of 0.05 and a statistical power of 80%, a total sample size of 26 participants were required to detect an effect size of 0.288 (G*Power, ANOVA: repeated measures, within-between interaction). We should add 20–30%% for dropouts that happen in most of the studies in this cohort, and then we should have included 31 participants at least. Since the effect size used (from previous data) is low, we consider this study to be a pilot trial.

We performed a post-hoc power calculation. Considering an effect size of 0.17, alfa 0.05, total sample size 23, 2 groups and 2 measurements, the power achieved was 0.34 (G*Power, ANOVA: repeated measures, within-between interaction).

Statistics. The normal distribution as well as the skewness and kurtosis of the data was checked using the Kolmogorov–Smirnov test. Results are presented as the median or mean (\pm the standard deviation [*SD*]). The Mann–Whitney U test was used to check differences between groups since the data did not follow a parametric distribution at baseline. Differences on categorical variables were checked with the Chi-Squared test. To analyze the effect of the exercise programs we used the ANOVA mixed model with time as the within-group factor and the exercise group as the between-group factor. A per-protocol analysis was performed instead of an intention to treat analysis. The SPSS package, version 20.0 for Windows (IBM Corp., Armonk, NY) was used for all the statistical analyses, results were recognized as statistically significant at a threshold cut-off of $p \le 0.05$ for all the statistical analyses.

Conclusion

There was no difference between a combined 16-week aerobic and muscle strength exercise program and a home-based program on physical activity levels and physical functioning (besides OLST). Both interventions were associated with positive changes of the outcomes

Received: 28 August 2019; Accepted: 15 April 2020;

Published online: 19 May 2020

References

- 1. Painter, P. Physical functioning in end-stage renal disease patients: Update 2005. Hemodial Int. 9(3), 218-235 (2005).
- Johansen, K. L., Chertow, G. M., Jin, C. & Kutner, N. G. Significance of Frailty among Dialysis Patients. J Am Soc Nephrol 18(11), 2960–2967 (2007).
- 3. Johansen, K. L. *et al.* Validation of questionnaires to estimate physical activity and functioning in end-stage renal disease. *Kidney Int* **59**(3), 1121–1127 (2001).

- Alvarez-Ude, F. & Adaptación, M. J. F. R. transcultural y validación preliminar de la versión española del Kidney Disease Questionnaire(Cuestionario de la enfermedad renal). Nefrología 17(6), 486–496 (1997).
- 5. Wang, A. Y.-M. Cardiac Valvular Calcification as a Marker of Atherosclerosis and Arterial Calcification in End-stage Renal Disease. *Arch Intern Med* **165**(3), 327 (2005).
- 6. Painter, P. L. et al. Effects of exercise training during hemodialysis. Nephron 43(2), 87-92 (1986).
- 7. Segura-Ortí, E. Ejercicio en pacientes en hemodiálisis: revisión sistemática de la literatura. Nefrología 30(2), 236-246 (2010).
 - Segura-Ortí, E., Rodilla-Alama, V., Lisón, F. & Fisioterapia, J. durante la hemodiálisis: resultados de un programa de fuerzaresistencia. Nefrología 28(1), 67–72 (2008).
 - Segura-Ortí, E., Kouidi, E. & Lisón, J. F. Effect of resistance exercise during hemodialysis on physical function and quality of life: randomized controlled trial. *Clin Nephrol* 71(05), 527–537 (2009).
- Esteve Simó, V. et al. Complete low-intensity endurance training programme in haemodialysis patients: improving the care of renal patients. Nephron Clin Pract 128(3-4), 387–393 (2014).
- Esteve Simo, V. et al. Beneficios del ejercicio físico de baja intensidad durante la sesión de hemodiálisis en el paciente anciano. Nefrología 35(4), 385-394 (2015).
- 12. Simó, V. E. *et al.* Efficacy of neuromuscular electrostimulation intervention to improve physical function in haemodialysis patients. *Int Urol Nephrol* **47**(10), 1709–1717 (2015).
- 13. Esteve, V. *et al.* Efecto de la electroestimulación neuromuscular sobre la fuerza muscular, capacidad funcional y composición corporal en los pacientes en hemodiálisis. *Nefrología* **37**(1), 68–77 (2017).
- Segura-Ortí, E. et al. Virtual reality exercise intradialysis to improve physical function: A feasibility randomized trial. Scand J Med Sci Sports 29(1), 89–94 (2019).
- 15. Heiwe, S. & Jacobson, S. H. Exercise training for adults with chronic kidney disease. *Cochrane Database Syst Rev* 10, CD003236 (2011).
- Konstantinidou, E., Koukouvou, G., Kouidi, E., Deligiannis, A. & Tourkantonis, A. Exercise training in patients with end-stage renal disease on hemodialysis: comparison of three rehabilitation programs. J Rehabil Med 34(1), 40–45 (2002).
- Fitts, S. S., Guthrie, M. R. & Blagg, C. R. Exercise coaching and rehabilitation counseling improve quality of life for predialysis and dialysis patients. *Nephron* 82(2), 115–121 (1999).
- Tao, X., Chow, S. K. Y. & Wong, F. K. Y. A nurse-led case management program on home exercise training for hemodialysis patients: A randomized controlled trial. *Int J Nurs Stud* 52(6), 1029–1041 (2015).
- Cook, S. A., MacLaughlin, H. & Macdougall, I. C. A structured weight management programme can achieve improved functional ability and significant weight loss in obese patients with chronic kidney disease. *Nephrol Dial Transplant* 23(1), 263–268 (2007).
- 20. Bulckaen, M. *et al.* Implementation of exercise training programs in a hemodialysis unit: effects on physical performance. *J Nephrol* 24(6), 790–797 (2011).
- Greenwood, S. A. et al. Evaluation of a pragmatic exercise rehabilitation programme in chronic kidney disease. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc 27(Suppl 3), iii126–134 (2012).
- 22. Malagoni, A. M. et al. Acute and long-term effects of an exercise program for dialysis patients prescribed in hospital and performed at home. J Nephrol 21(6), 871–878 (2008).
- Koh, K. P., Fassett, R. G., Sharman, J. E., Coombes, J. S. & Williams, A. D. Effect of Intradialytic Versus Home-Based Aerobic Exercise Training on Physical Function and Vascular Parameters in Hemodialysis Patients: A Randomized Pilot Study. Am J Kidney Dis 55(1), 88–99 (2010).
- 24. Bohm, C. *et al.* Effects of intradialytic cycling compared with pedometry on physical function in chronic outpatient hemodialysis: a prospective randomized trial. *Nephrol Dial Transplant* **29**(10), 1947–1955 (2014).
- Leehey, D. J. et al. Aerobic exercise in obese diabetic patients with chronic kidney disease: a randomized and controlled pilot study. Cardiovasc Diabetol 8(1), 62 (2009).
- Rezaei, J., Abdi, A., Rezaei, M., Heydarnezhadian, J. & Jalali, R. Effect of Regular Exercise Program on Depression in Hemodialysis Patients. Int Sch Res Not 2015, 1–6 (2015).
- 27. Deligiannis, A. et al. Cardiac effects of exercise rehabilitation in hemodialysis patients. Int J Cardial 70(3), 253-266 (1999).
- Manfredini, F. et al. Exercise in Patients on Dialysis: A Multicenter, Randomized Clinical Trial. J Am Soc Nephrol 28(4), 1259–1268 (2017).
- Zamojska, S., Szklarek, M., Niewodniczy, M. & Nowicki, M. Correlates of habitual physical activity in chronic haemodialysis patients. Nephrol Dial Transplant 21(5), 1323–1327 (2006).
- Johansen, K. L. et al. Physical activity levels in patients on hemodialysis and healthy sedentary controls. Kidney Int 57(6), 2564–2570 (2000).
- Baria, F. et al. Randomized controlled trial to evaluate the impact of aerobic exercise on visceral fat in overweight chronic kidney disease patients. Nephrol Dial Transplant 29(4), 857–864 (2014).
- 32. Painter, P. Exercise for patients with chronic disease: Physician responsibility. Curr Sports Med Rep 2(3), 173-180 (2003).
- 33. Cook, W. L. & Jassal, S. V. Functional dependencies among the elderly on hemodialysis. *Kidney Int* **73**(11), 1289–1295 (2008).
- 34. Matsuzawa, R. *et al.* Habitual Physical Activity Measured by Accelerometer and Survival in Maintenance Hemodialysis Patients. *Clin J Am Soc Nephrol* 7(12), 2010–2016 (2012).
- Beddhu, S., Baird, B. C., Zitterkoph, J., Neilson, J. & Greene, T. Physical Activity and Mortality in Chronic Kidney Disease (NHANES III). Clin J Am Soc Nephrol 4(12), 1901–1906 (2009).
- 36. Johansen, K. L. *et al.* Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial. *J Am Soc Nephrol JASN* **17**(8), 2307–2314 (2006).
- 37. Johansen, K. L. Exercise in the End-Stage Renal Disease Population. J Am Soc Nephrol 18(6), 1845–1854 (2007).
- Segura-Ortí, E. & Martínez-Olmos, F. J. Test-Retest Reliability and Minimal Detectable Change Scores for Sit-to-Stand-to-Sit Tests, the Six-Minute Walk Test, the One-Leg Heel-Rise Test, and Handgrip Strength in People Undergoing Hemodialysis. *Phys Ther* 91(8), 1244–1252 (2011).
- 39. Heiwe, S. & Jacobson, S. H. Exercise training in adults with CKD: a systematic review and meta-analysis. *Am J Kidney Dis Off J Natl Kidney Found* **64**(3), 383–393 (2014).
- 40. MCBA, vanV., Greef, de & Huisman, M. H. G. RM. The effects of a low-to-moderate intensity pre-conditioning exercise programme linked with exercise counselling for sedentary haemodialysis patients in The Netherlands: results of a randomized clinical trial. *Nephrol Dial Transplant* 20(1), 141–146 (2005).
- Headley, S. et al. Resistance training improves strength and functional measures in patients with end-stage renal disease. Am J Kidney Dis Off J Natl Kidney Found 40(2), 355–364 (2002).
- 42. Oliveros, R. M. S. et al. Estudio piloto sobre entrenamiento físico durante hemodiálisis. Rev Médica Chile 139(8), 1046–1053 (2011).
- 43. Orcy, R. B., Dias, P. S., Seus, T. L., Barcellos, F. C. & Bohlke, M. Combined Resistance and Aerobic Exercise is Better than Resistance Training Alone to Improve Functional Performance of Haemodialysis Patients - Results of a Randomized Controlled Trial: Exercise in Dialysis Patients. *Physiother Res Int* 17(4), 235–243 (2012).
- 44. Silva, S. F. et al. Physical therapy during hemodialyse in patients with chronic kidney disease. J Bras Nefrol Orgao Of Soc Bras E Lat-Am Nefrol 35(3), 170–176 (2013).
- 45. Kouidi, E. *et al.* Depression, heart rate variability, and exercise raining in dialysis patients. *Eur J Cardiovasc Prev Rehabil* 17(2), 160–167 (2010).

- 46. Heiwe, S. & Tollin, H. Patients' perspectives on the implementation of intra-dialytic cycling—a phenomenographic study. *Implement Sci IS* 7, 68 (2012).
- 47. Ortega-Pérez de Villar L. Comparison of two exercise programs for hemodialysis patients, intradialysis vs home based program. Absolute and relative reliability of physical performance. (2017).
- Fix AJ, Daughton D, Psychological Assessment Resources I. Human Activity Profile: Professional Manual. Odessa, Fla. (P.O. Box 998, Odessa 33556): Psychological Assessment Resources; (1988).
- Overend, T., Anderson, C., Sawant, A., Perryman, B. & Locking-Cusolito, H. Relative and Absolute Reliability of Physical Function Measures in People with End-Stage Renal Disease. *Physiother Can* 62(2), 122–128 (2010).
- Ortega-Pérez de Villar, L. et al. Test-retest reliability and minimal detectable change scores for the short physical performance battery, one-legged standing test and timed up and go test in patients undergoing hemodialysis. PloS One 13(8), e0201035 (2018).
- Washurn, R. A., Smith, K. W., Jette, A. M. & Janney, C. A. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol 46(2), 153–162 (1993).
- Hedayati, S. S., Bosworth, H. B., Kuchibhatla, M., Kimmel, P. L. & Szczech, L. A. The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. *Kidney Int* 69(9), 1662–1668 (2006).
- 53. Hays, R. D., Kallich, J. D., Mapes, D. L., Coons, S. J. & Carter, W. B. Development of the kidney disease quality of life (KDQOL) instrument. *Qual Life Res Int J Qual Life Asp Treat Care Rehabil* **3**(5), 329–338 (1994).
- 54. Pérez-Domínguez B. Comparación de los efectos de un programa de ejercicio intradiálisis frente a un programa de ejercicio domiciliario. (2017).

Acknowledgements

We would like to thank all the staff from the *Hospital Doctor Peset* and *Clínica Virgen del Consuelo* HD units in Valencia (Spain) for their help in completing this study. We also thank the physical therapy students and staff from the Physical Therapy Department at the *Universidad CEU Cardenal Herrera* for their support in assessing the participants. This project was supported by a 2017–2018 research and teaching projects support grant from the CEU-UCH (grant code IDOC17/19).

Author contributions

L.O.P.d.V.: design the work, performed the data analysis and the interpretation of data, wrote the main manuscript text and prepare all the figures (this person was drawn figures with one program). E.S.O., design the work, performed the data analysis and the interpretation of data, wrote the main manuscript text and prepare all the figures. Convinced and designed the analysis. F.J.M.O. collected data F.B.P.D. collected data V.B.C. collected data. F.J.M.A. collected data. T.M. had a critical revision

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to L.O.-P.d.V.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020